Anteris Technologies Global Corp. — Capital/Financing Update 2018

Jun 20, 2018

21.06.18

==> picture [452 x 24] intentionally omitted <==

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

RECIEPT OF PLACEMENT FUNDS FROM DIRECTORS

Admedus Limited (ASX:AHZ) today confirms it has received funds totalling $700k from its Directors, fulfilling their commitment to participate in the recent placement offer at 30c per share, and demonstrating their confidence in the Company’s development strategy.

The investment amounts were as previously described: Mathew Ratty (former director) $500k; Wayne Paterson $50k; John Seaberg $50k and Simon Buckingham $100k.

The Director’s subscription will be held in escrow, and the allocation of Director’s shares will take place, subject to shareholder approval, after the Extraordinary General Meeting (EGM).

The EGM will be held at 9.00am (AEST) on Thursday, 28 June 2018, and will be chaired by Executive Director and Company Secretary, Catherine Costello, who will present the resolutions to those in physical attendance. The remaining Directors will attend remotely.

The meeting presentation will be limited to the resolutions only and voting results will be published on the ASX platform following the conclusion of the EGM.

A full shareholder update will be provided after the release of the half-yearly financial report.

ENDS

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

For more information, please contact:

Admedus Limited Barb Ferres +61 7 3152 3216

Admedus Limited ABN 35 088 221 078

Registered Office Level 9 301 Coronation Drive Milton QLD 4064

Customer Service T 1300 550 310 F 1300 880 398 International T: +61 8 9266 0100 F: +61 8 9266 0199

E: info@admedus.com W: www.admedus.com Brisbane • Minneapolis Zurich • Singapore